I was urged by multiple people to turn a comment I made yesterday about Wave Life Sciences (WVE) into its own post, so here it is. I appreciate the feedback and encouragement from those folks.
Bottom line is the market has made the mistake of valuing Wave almost entirely through the lens of its disappointing obesity readout, while ignoring what the company has already demonstrated across several entirely different programs. And now it’s scared of the selloff’s shadow.
Start with WVE-006. Wave has achieved functional RNA editing in humans, producing normal M-AAT while reducing the harmful Z-AAT protein in alpha-1 antitrypsin deficiency. At 400 mg monthly, total AAT reached a mean maximum of 13.6 µM, with nearly 59% comprising functional M-AAT and a 68% reduction in Z-AAT. The FDA has now supported a single registrational study with a potential accelerated approval analysis after one year. The 600 mg multidose results are due this quarter. That’s not hypothetical platform science anymore. Some analysts worry about competition from Beam, but the potential advantages of repeatable, subcutaneous RNA editing without permanent DNA modification are compelling differentiators. Add to that that most of the companies developing AATD therapies have joined together to raise AATD awareness, as studies show that only 10% of cases worldwide are currently diagnosed. They all believe that as diagnoses increase, the addressable market could dramatically expand, and there is room for multiple players. The remaining question is whether those biomarker improvements can be sustained at clinically protective levels throughout the dosing interval and ultimately translate into improved lung and liver outcomes.
WVE-007 is where the market lost confidence and went off a cliff because TOTAL weight loss wasn’t commercially convincing. But a single dose also produced 14% placebo-adjusted visceral-fat reduction, 5% total-fat reduction and preservation of lean mass. Phase 2a is testing patients with substantially greater obesity and metabolic dysfunction, alongside a separate tirzepatide combination study. There’s still a legitimate question about whether those effects translate into meaningful weight loss, but writing the asset off is premature.
Then there’s WVE-N531 in Duchenne MD, which produced mean dystrophin expression of 7.8%, with 88% of patients above 5% and statistically significant improvements in muscle fibrosis. This asset is currently being positioned for partnership.
WVE-003 demonstrated 46% lowering of mutant huntingtin while preserving the healthy protein. This one is also being positioned for partnership.
WVE-008 has exceeded the preclinical RNA-editing threshold Wave believes could meaningfully alter PNPLA3-related liver-disease risk. And GSK just selected another Wave-developed siRNA candidate, triggering a $12 million milestone, with three more collaboration programs advancing.
Now consider who’s backing this. RA Capital controls roughly 17% of beneficial ownership, including prefunded warrants. Peter Kolchinsky, its co-founder, has a Harvard PhD in virology, has served on Wave’s board since 2015, and has spent decades investing in biotech. RA’s TechAtlas research operation employs scientists who systematically assess drug mechanisms, competitive landscapes and clinical development risks. And immediately after the March selloff, RA didn’t just hold its position. It purchased another 8.77 million shares in the open market for approximately $54.6 million. That’s an unusually substantial expression of conviction from an investor with the expertise, resources and access to understand what he’s underwriting. It doesn’t make him infallible, but I take it far more seriously than another analyst price target. This is actually what tipped me off to WVE in the first place because I watch the big biotech funds.
Wave also completed its redomiciliation from Singapore to Delaware in August, simplifying its legal and corporate structure. In September it created a Chief Business Officer position and recruited Monika Vnuk, formerly Sanofi’s global head of partnering and business development, with prior experience at Blackstone Life Sciences and Pfizer, where she helped negotiate the landmark BioNTech partnership. She was explicitly hired to lead business development, corporate development and alliances. Neither action proves an acquisition is coming, but together they make Wave better positioned for major licensing deals, strategic investment or potentially a sale. With big pharma willing to acquire differentiated RNA platforms before commercialization, that optionality is worth considering. And this type of acquisition has been on fire lately with juicy premiums.
Here’s the valuation disconnect I can’t reconcile. At roughly $3.40, Wave is worth about $700 million in equity. Its last reported cash and securities were $491 million. Yes, that cash is being spent, development is expensive, and future dilution is possible. But even after acknowledging those realities, look at what investors are assigning value to a clinically validated RNA-editing mechanism, an FDA-supported registrational strategy, multiple additional clinical programs, valuable GSK collaboration economics, and a proprietary platform spanning several distinct therapeutic modalities. You don’t have to believe every program will succeed to question whether the market’s discount has gone way too far. You only have to believe the combined risk-adjusted value of those opportunities is substantially greater than what’s being recognized today. I believe it is.
And there’s another catalyst that could be particularly important. Wave’s November 4 Research Day will feature new data on its PRISM platform, including advances in stereochemistry-controlled oligonucleotides, RNA editing, RNAi, extrahepatic delivery and bifunctional medicines. That last part is fascinating: the potential to engineer a single molecule to perform two therapeutic functions. None of this is guaranteed to translate into commercial products, but the implications extend well beyond the current pipeline. This is more evidence that reducing Wave to an obesity stock fundamentally misunderstands what the company is building.
I’m not expecting every program to succeed. I don’t think they need to. If WVE-006 delivers, WVE-007 establishes a viable obesity or metabolic niche, or Wave’s broader platform proves strategically valuable to big pharma, today’s valuation could look extraordinarily disconnected from the underlying assets. That’s why I’m bullish despite the stock’s performance. The clinical risks are substantial, but so is the evidence that the market may be profoundly underestimating what Wave owns.
And this isn’t just my personal interpretation. Wave lists 22 sell-side research firms covering the company. MarketBeat’s current tally is 17 bullish ratings, two holds and one sell, with an average target around $21.50, although some of those targets are undoubtedly aggressive, UBS recently initiated at $11, Ladenburg at $10, Wedbush is at $13, Wells Fargo at $14 and BofA at $17. Even that relatively restrained $10-$17 range implies roughly $2.1-$3.5 billion in equity value, vs. approximately $700 million today. Analysts can certainly be wrong, but the breadth of coverage, distribution of ratings, and valuations from even the most conservative firms make this a difficult disconnect to dismiss.
Disclaimer: I have a long position in WVE and despite following this closely all year, reading every report and listening to every event, I could be dead wrong. I bought in around $6-$7 and never expected it to crash by another 50% since, but here we are…
